You are here:Home-Inhibitors & Agonists-Cytoskeleton/Cell Adhesion Molecules-Selectin

Request The Product List ofSelectin Selectin

Cat. No. Product Name CAS No. Information
PC-61443

Rivipansel sodium

1189037-60-2

Rivipansel sodium (GMI-1070, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.

Anemia

Phase 3 Clinical

PC-61286

GMI-1070

927881-99-0

GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.

Anemia

Phase 3 Clinical

PC-60181

HMCEF

2002363-68-8

A novel P-selectin inhibitor that directly binds to P-selectin; intercalates into calf thymus DNA, cuts off DNA pBR22 and inhibits the proliferation of cancer cells; dose dependently inhibits inflammatory response of mice and inhibits thrombosis and inflammation, decreases serum TNFα and IL-8.

PC-61287

PSI-421

1067186-56-4 A potent, orally bioavailable P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.
PC-61285

GMI-1271

1914993-95-5 A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM; weakly inhibits L-selectin (IC50=2.9 uM) and >10 uM for P-selectin; not only mobilizes AML cells out of protective niches but also blocks NF-kB activation and prevents this E-selectin-mediated chemoresistance, thereby enhancing the therapeutic effects of standard chemotherapy; also overcomes MM metastasis and chemoresistance.

Blood Cancer

Phase 2 Clinical

PC-61284

GMI-1257

A dual inhibitor of E selectin and CXCR4 with IC50 of 3.6 uM and 1.1 uM respectively, blocks adhesion of AML blasts to E-Selectin, mobilizes human AML engrafted in mice; inhibits E-selectin and SDF-1 mediated chemotaxis in a transwell-based assay, effectively mobilizes leukemia from the marrow and reduces the bone marrow burden of AML in combination with chemotherapy.
PC-61283

GMI-1215

A dual inhibitor of E selectin and CXCR4 with IC50 of 4.1 uM and 30 nM respectively, blocks adhesion of AML blasts to E-Selectin, mobilizes human AML engrafted in mice; inhibits E-selectin and SDF-1 mediated chemotaxis in a transwell-based assay, effectively mobilizes leukemia from the marrow and reduces the bone marrow burden of AML in combination with chemotherapy.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com